EP2583663A1 - Oil-in-water type emulsion skin cosmetic - Google Patents
Oil-in-water type emulsion skin cosmetic Download PDFInfo
- Publication number
- EP2583663A1 EP2583663A1 EP11795586.4A EP11795586A EP2583663A1 EP 2583663 A1 EP2583663 A1 EP 2583663A1 EP 11795586 A EP11795586 A EP 11795586A EP 2583663 A1 EP2583663 A1 EP 2583663A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- acid
- skin
- iob
- salt
- ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 239000000839 emulsion Substances 0.000 title claims abstract description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 57
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- 235000011187 glycerol Nutrition 0.000 claims abstract description 29
- 229920001577 copolymer Polymers 0.000 claims abstract description 24
- 150000008574 D-amino acids Chemical class 0.000 claims abstract description 21
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims abstract description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229920006037 cross link polymer Polymers 0.000 claims abstract description 6
- 239000010696 ester oil Substances 0.000 claims abstract description 6
- 229920001519 homopolymer Polymers 0.000 claims abstract description 6
- 239000000470 constituent Substances 0.000 claims abstract description 4
- 239000004615 ingredient Substances 0.000 claims description 75
- 229920000536 2-Acrylamido-2-methylpropane sulfonic acid Polymers 0.000 claims description 19
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 claims description 19
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 11
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 239000007764 o/w emulsion Substances 0.000 claims description 5
- KGKQNDQDVZQTAG-UHFFFAOYSA-N 8-methylnonyl 2,2-dimethylpropanoate Chemical compound CC(C)CCCCCCCOC(=O)C(C)(C)C KGKQNDQDVZQTAG-UHFFFAOYSA-N 0.000 claims description 4
- HNDYULRADYGBDU-UHFFFAOYSA-N 8-methylnonyl benzoate Chemical compound CC(C)CCCCCCCOC(=O)C1=CC=CC=C1 HNDYULRADYGBDU-UHFFFAOYSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 4
- SZLIWAKTUJFFNX-UHFFFAOYSA-N dihydrocitronellol benzoate Natural products CC(C)CCCC(C)CCOC(=O)C1=CC=CC=C1 SZLIWAKTUJFFNX-UHFFFAOYSA-N 0.000 claims description 4
- 229940047670 sodium acrylate Drugs 0.000 claims description 4
- PMMYEEVYMWASQN-IUYQGCFVSA-N trans-4-hydroxy-D-proline Chemical compound O[C@@H]1CN[C@@H](C(O)=O)C1 PMMYEEVYMWASQN-IUYQGCFVSA-N 0.000 claims description 4
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 claims description 3
- AYUKNFXLSTVUAB-UHFFFAOYSA-N 2-[2-[2-(2,2-dimethylpropanoyloxy)propoxy]propoxy]propyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC(C)COC(C)COC(C)COC(=O)C(C)(C)C AYUKNFXLSTVUAB-UHFFFAOYSA-N 0.000 claims description 3
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 3
- 229930195711 D-Serine Natural products 0.000 claims description 3
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 3
- 229930182847 D-glutamic acid Natural products 0.000 claims description 3
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims description 3
- 229930182818 D-methionine Natural products 0.000 claims description 3
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 3
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 claims description 2
- OUCGJMIVSYHBEC-UHFFFAOYSA-N 2-ethylhexyl 2-ethylhexanoate Chemical compound CCCCC(CC)COC(=O)C(CC)CCCC OUCGJMIVSYHBEC-UHFFFAOYSA-N 0.000 claims description 2
- NAGVKZOTMXGCCA-UHFFFAOYSA-N 2-ethylhexyl 7-methyloctanoate Chemical compound CCCCC(CC)COC(=O)CCCCCC(C)C NAGVKZOTMXGCCA-UHFFFAOYSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims description 2
- 229930182820 D-proline Natural products 0.000 claims description 2
- 229930195710 D‐cysteine Natural products 0.000 claims description 2
- DRRMRHKHTQRWMB-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-bis(2-ethylhexanoyloxymethyl)propyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(COC(=O)C(CC)CCCC)(COC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DRRMRHKHTQRWMB-UHFFFAOYSA-N 0.000 claims description 2
- WMNULTDOANGXRT-UHFFFAOYSA-N bis(2-ethylhexyl) butanedioate Chemical compound CCCCC(CC)COC(=O)CCC(=O)OCC(CC)CCCC WMNULTDOANGXRT-UHFFFAOYSA-N 0.000 claims description 2
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 claims description 2
- ZQXSMRAEXCEDJD-UHFFFAOYSA-N n-ethenylformamide Chemical compound C=CNC=O ZQXSMRAEXCEDJD-UHFFFAOYSA-N 0.000 claims 1
- 239000004584 polyacrylic acid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 26
- 239000002562 thickening agent Substances 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 238000009472 formulation Methods 0.000 abstract 2
- DZSVIVLGBJKQAP-UHFFFAOYSA-N 1-(2-methyl-5-propan-2-ylcyclohex-2-en-1-yl)propan-1-one Chemical compound CCC(=O)C1CC(C(C)C)CC=C1C DZSVIVLGBJKQAP-UHFFFAOYSA-N 0.000 abstract 1
- -1 fatty acid glycerin ester Chemical class 0.000 description 33
- 238000011156 evaluation Methods 0.000 description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000006071 cream Substances 0.000 description 13
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000003921 oil Substances 0.000 description 11
- 239000008346 aqueous phase Substances 0.000 description 10
- 230000003020 moisturizing effect Effects 0.000 description 10
- 229920001296 polysiloxane Polymers 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 9
- 239000002211 L-ascorbic acid Substances 0.000 description 8
- 235000000069 L-ascorbic acid Nutrition 0.000 description 8
- 229960005070 ascorbic acid Drugs 0.000 description 8
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- 229940058015 1,3-butylene glycol Drugs 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 235000019437 butane-1,3-diol Nutrition 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- 239000002304 perfume Substances 0.000 description 6
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical class NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 6
- 230000002087 whitening effect Effects 0.000 description 6
- 150000008575 L-amino acids Chemical group 0.000 description 5
- 239000010419 fine particle Substances 0.000 description 5
- FWFUWXVFYKCSQA-UHFFFAOYSA-M sodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C FWFUWXVFYKCSQA-UHFFFAOYSA-M 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229960000401 tranexamic acid Drugs 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 4
- IWWCATWBROCMCW-UHFFFAOYSA-N batyl alcohol Natural products CCCCCCCCCCCCCCCCCCOC(O)CO IWWCATWBROCMCW-UHFFFAOYSA-N 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 230000000149 penetrating effect Effects 0.000 description 4
- 229960005323 phenoxyethanol Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000003892 spreading Methods 0.000 description 4
- 230000007480 spreading Effects 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- 230000000475 sunscreen effect Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 3
- IZZIWIAOVZOBLF-UHFFFAOYSA-N 5-methyloxysalicylic acid Natural products COC1=CC=C(O)C(C(O)=O)=C1 IZZIWIAOVZOBLF-UHFFFAOYSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical compound C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- AUZQQIPZESHNMG-UHFFFAOYSA-N 3-methoxysalicylic acid Chemical compound COC1=CC=CC(C(O)=O)=C1O AUZQQIPZESHNMG-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- MRIXVKKOHPQOFK-UHFFFAOYSA-N 4-methoxysalicylic acid Chemical compound COC1=CC=C(C(O)=O)C(O)=C1 MRIXVKKOHPQOFK-UHFFFAOYSA-N 0.000 description 2
- IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 2
- XDBMXUKHMOFBPJ-ZAFYKAAXSA-N L-ascorbic acid 2-sulfate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OS(O)(=O)=O)=C1O XDBMXUKHMOFBPJ-ZAFYKAAXSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 244000302544 Luffa aegyptiaca Species 0.000 description 2
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 229940092738 beeswax Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940009662 edetate Drugs 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical class OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 108010028309 kalinin Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 229940078812 myristyl myristate Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 229940100460 peg-100 stearate Drugs 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- AFQOCSDOKGNDNA-OBEHBXMUSA-N (2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one (Z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCC\C=C/CCCCCCCC(O)=O AFQOCSDOKGNDNA-OBEHBXMUSA-N 0.000 description 1
- VBURMNYQYXSQEL-VFAVKCLXSA-N (2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one (Z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O VBURMNYQYXSQEL-VFAVKCLXSA-N 0.000 description 1
- IRVNEGRHQKGRGD-WPXUHFOISA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;hexadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O IRVNEGRHQKGRGD-WPXUHFOISA-N 0.000 description 1
- PBTPTBMYJPCXRQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;hexadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O PBTPTBMYJPCXRQ-MGMRMFRLSA-N 0.000 description 1
- MHUOEHQATDLJFZ-WPXUHFOISA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O MHUOEHQATDLJFZ-WPXUHFOISA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- UAFHRUBCOQPFFM-UHFFFAOYSA-N 1-(aminomethyl)cyclohexane-1-carboxylic acid Chemical compound NCC1(C(O)=O)CCCCC1 UAFHRUBCOQPFFM-UHFFFAOYSA-N 0.000 description 1
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 1
- JPPRXACMNPYJNK-UHFFFAOYSA-N 1-docosoxydocosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCCCCCC JPPRXACMNPYJNK-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZYDQSPYFLQSONW-UHFFFAOYSA-N 2,3-dimethoxy-3-(2-methoxyphenyl)prop-2-enoic acid Chemical compound COC(C(O)=O)=C(OC)C1=CC=CC=C1OC ZYDQSPYFLQSONW-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- JUIYTAQAHOONSH-UHFFFAOYSA-N 2-hydroxy-4-propan-2-yloxybenzoic acid Chemical compound CC(C)OC1=CC=C(C(O)=O)C(O)=C1 JUIYTAQAHOONSH-UHFFFAOYSA-N 0.000 description 1
- IXKMJGZLCSWMTD-UHFFFAOYSA-N 2-hydroxy-4-propoxybenzoic acid Chemical compound CCCOC1=CC=C(C(O)=O)C(O)=C1 IXKMJGZLCSWMTD-UHFFFAOYSA-N 0.000 description 1
- AAUQLHHARJUJEH-UHFFFAOYSA-N 2-hydroxy-5-methoxybenzoic acid Natural products COC1=CC=CC(O)=C1C(O)=O AAUQLHHARJUJEH-UHFFFAOYSA-N 0.000 description 1
- VHCJSVNQEBEVMO-UHFFFAOYSA-N 2-hydroxy-5-propoxybenzoic acid Chemical compound CCCOC1=CC=C(O)C(C(O)=O)=C1 VHCJSVNQEBEVMO-UHFFFAOYSA-N 0.000 description 1
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 description 1
- PKYUNJWBVAXPMG-UHFFFAOYSA-N 3-ethoxy-2-hydroxybenzoic acid Chemical compound CCOC1=CC=CC(C(O)=O)=C1O PKYUNJWBVAXPMG-UHFFFAOYSA-N 0.000 description 1
- NDHNBHXAALUAAJ-UHFFFAOYSA-N 4,5-dimorpholin-4-yl-1h-pyridazin-6-one Chemical compound C1COCCN1C=1C(O)=NN=CC=1N1CCOCC1 NDHNBHXAALUAAJ-UHFFFAOYSA-N 0.000 description 1
- JBRMEFWJFBHUKG-UHFFFAOYSA-N 4-[(diaminomethylideneamino)methyl]cyclohexane-1-carboxylic acid Chemical compound NC(N)=NCC1CCC(C(O)=O)CC1 JBRMEFWJFBHUKG-UHFFFAOYSA-N 0.000 description 1
- RNGFVIMNTYOBTK-UHFFFAOYSA-N 4-butoxy-2-hydroxybenzoic acid Chemical compound CCCCOC1=CC=C(C(O)=O)C(O)=C1 RNGFVIMNTYOBTK-UHFFFAOYSA-N 0.000 description 1
- DVZPQHRWOUXUPU-UHFFFAOYSA-N 4-ethoxy-2-hydroxybenzoic acid Chemical compound CCOC1=CC=C(C(O)=O)C(O)=C1 DVZPQHRWOUXUPU-UHFFFAOYSA-N 0.000 description 1
- WMNORUTYNGVDKW-UHFFFAOYSA-N 4-ethyl-2-[(4-methoxyphenyl)methylidene]octanoic acid;octyl 3-(4-methoxyphenyl)prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=CC1=CC=C(OC)C=C1.CCCCC(CC)CC(C(O)=O)=CC1=CC=C(OC)C=C1 WMNORUTYNGVDKW-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- ZZKFPIOJAOEMQL-UHFFFAOYSA-N 5-ethoxy-2-hydroxybenzoic acid Chemical compound CCOC1=CC=C(O)C(C(O)=O)=C1 ZZKFPIOJAOEMQL-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 244000274847 Betula papyrifera Species 0.000 description 1
- 235000009113 Betula papyrifera Nutrition 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 235000010928 Betula populifolia Nutrition 0.000 description 1
- 235000002992 Betula pubescens Nutrition 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- SEOSLUZKTRBVTI-AULYBMBSSA-N C1=CC(OC)=CC=C1C(=O)NC[C@@H]1CC[C@@H](C(O)=O)CC1 Chemical compound C1=CC(OC)=CC=C1C(=O)NC[C@@H]1CC[C@@H](C(O)=O)CC1 SEOSLUZKTRBVTI-AULYBMBSSA-N 0.000 description 1
- AVWTXYWHGFHGQD-ZKCHVHJHSA-N CNC(=O)[C@H]1CC[C@H](CN)CC1 Chemical compound CNC(=O)[C@H]1CC[C@H](CN)CC1 AVWTXYWHGFHGQD-ZKCHVHJHSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 101710097070 D-aminoacylase Proteins 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 241000209485 Nuphar Species 0.000 description 1
- YQINWFJNFJEWHH-UCLHFMLVSA-N OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O YQINWFJNFJEWHH-UCLHFMLVSA-N 0.000 description 1
- NGUBAXUPKACQCL-UCLHFMLVSA-N OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O NGUBAXUPKACQCL-UCLHFMLVSA-N 0.000 description 1
- QDTPSCIFGGYXJD-IPKXSQMUSA-N OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O QDTPSCIFGGYXJD-IPKXSQMUSA-N 0.000 description 1
- GAKOHFNTEXOHTP-RXSVEWSESA-N OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O GAKOHFNTEXOHTP-RXSVEWSESA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000015422 Rumex crispus ssp. crispus Nutrition 0.000 description 1
- 235000015426 Rumex crispus ssp. fauriei Nutrition 0.000 description 1
- 244000207667 Rumex vesicarius Species 0.000 description 1
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 1
- 241001647091 Saxifraga granulata Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 239000006087 Silane Coupling Agent Substances 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001530209 Swertia Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- UDRYFKCHZFVZGJ-UHFFFAOYSA-N [5-hexadecanoyloxy-4-(hexadecanoyloxymethyl)-6-methylpyridin-3-yl]methyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC1=CN=C(C)C(OC(=O)CCCCCCCCCCCCCCC)=C1COC(=O)CCCCCCCCCCCCCCC UDRYFKCHZFVZGJ-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical compound OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 description 1
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- TUKWPCXMNZAXLO-UHFFFAOYSA-N ethyl 2-nonylsulfanyl-4-oxo-1h-pyrimidine-6-carboxylate Chemical compound CCCCCCCCCSC1=NC(=O)C=C(C(=O)OCC)N1 TUKWPCXMNZAXLO-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940074052 glyceryl isostearate Drugs 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- WPEXVRDUEAJUGY-UHFFFAOYSA-B hexacalcium;(2,3,4,5,6-pentaphosphonatooxycyclohexyl) phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OC1C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C1OP([O-])([O-])=O WPEXVRDUEAJUGY-UHFFFAOYSA-B 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000005375 organosiloxane group Chemical group 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- 239000012186 ozocerite Substances 0.000 description 1
- ZQTHOIGMSJMBLM-BUJSFMDZSA-N pangamic acid Chemical compound CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O ZQTHOIGMSJMBLM-BUJSFMDZSA-N 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- YRJKYHIIYRGTCC-UHFFFAOYSA-M potassium;2-hydroxy-4-methoxybenzoate Chemical compound [K+].COC1=CC=C(C([O-])=O)C(O)=C1 YRJKYHIIYRGTCC-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229930192014 saikosaponin Natural products 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
- A61K8/8182—Copolymers of vinyl-pyrrolidones. Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the invention relates to an oil-in-water type emulsion skin cosmetic composition having good texture and stability. More specifically, the invention relates to an oil-in-water type emulsion skin cosmetic composition having light spreadability on skin, no stickiness, lightness, a good feeling as an active ingredient effectively penetrates into the skin (good penetrating feeling), and high stability over time.
- Glycerin is known as a cosmetic ingredient having a high moisturizing effect and a high skin improving effect such as a high skin roughness reducing effect. To produce such a high skin improving effect significantly, glycerin is often added at a content of 5.0% by mass or more. Particularly, skin cosmetics with high glycerin content can produce high skin improving effect but may have the disadvantage in use that as the content increases, dewy feeling or feeling as an active ingredient penetrates into the skin disappears, and stickiness appears.
- acrylamide thickeners which are used as cosmetic thickeners, provide good texture such as good compatibility to the skin or good spreadability (see for example Patent Documents 4 and 5).
- Such acrylamide thickeners are useful as an alternative to carboxyvinyl polymer, xanthan gum, or hydroxyethyl cellulose, which is traditionally used as a cosmetic thickener in many cases.
- glycerin is added at a high concentration to provide a skin improving effect, a problem also occurs in which good texture of acrylamide thickeners is lost and it becomes impossible to reduce the glycerin-induced stickiness.
- an oil-in-water type emulsion skin cosmetic composition containing (A) a D-amino acid or a derivative or salt thereof, (B) a homopolymer, a copolymer, or a crosspolymer including, as a constituent unit, one or more selected from 2-acrylamido-2-methylpropanesulfonic acid, acrylic acid, and derivatives thereof, (C) an ester oil with an IOB value of 0.2 to 0.6, and (D) glycerin is compatible to the skin and not sticky during use, and can reliably produce a skin improving effect.
- an oil-in-water type emulsion skin cosmetic composition that has light spreadability on skin, no stickiness, and a good penetrating feeling when an active ingredient penetrates the skin, provides moisture, and is moist even in a system with a high glycerin content, and also allows glycerin to produce a high skin improving effect.
- the skin cosmetic composition of the invention essentially contains a D-amino acid or a derivative or salt thereof (ingredient (A), hereinafter also abbreviated as "D-amino acid maternal").
- D-amino acid or a derivative or salt thereof D-amino acid material
- D-amino acid material means a D-amino acid, a derivative thereof, a salt thereof, or a mixture thereof.
- amino acids can exist in L-form or D-form which are optical isomers and natural proteins are composed of L-amino acids bonded together by peptide bonds. It has been considered that except for some cases such as bacterial cell walls, only L-amino acids exist in mammals including human and only L-amino acids are used in living bodies. Conventionally, therefore, academic or industrial focus and research have been dominantly on L-amino acids.
- Exceptional cases where D-amino acids are used include (1) cases where D-amino acids are used as raw materials for antibiotics to be produced by bacteria and (2) cases where food additives contain a mixture of L- and D-amino acids in order to avoid the cost required to isolate the L-amino acid from the mixture (racemic mixture) containing equal amounts of the Land D-amino acids synthesized chemically.
- D-aspartic acid which does not occur naturally, increases with age in the ocular lens, brain, or skin, and the relationship between it and the development of cataract or Alzheimer's disease has begun to be discussed ( Tadatoshi Kinouchi et al. "proteins, Nucleic Acids, and Enzymes” (in Japanese) Vol. 50, No. 5 (2005), 453-560 ).
- D-Asp be used as a molecular marker for detecting skin damage caused by aging or ultraviolet rays.
- D-amino acids are positively used as biologically active materials.
- the invention is characterized in that a D-amino acid, which has not been conventionally added to cosmetics, especially skin cosmetics, is added as an essential ingredient.
- the D-amino acid material (ingredient (A)) used in the invention may be of any type as long as it is in the D-form.
- the D-amino acid material itself can be effective in improving the skin.
- examples include D-aspartic acid, which can have an antioxidant effect and a collagen production promoting effect, D-alanine, which can have a laminin 332 production promoting effect and a collagen production promoting effect, D-glutamic acid, which can have a barrier recovery function, a wrinkle formation reducing effect, and a skin roughness reducing effect, D-serine, which can have an ultraviolet damage reducing effect, D-hydroxyproline, which can have a laminin 332 production promoting effect, D-cysteine, which can have an ultraviolet damage reducing effect, D-methionine and D-proline, which can have an ultraviolet damage reducing effect, and D-hydroxyproline, which can have a melanin production inhibiting effect.
- the D-amino acid material used in the invention may be a synthetic product or a commercially available product.
- a known method for producing a D-amino acid includes allowing bacterial D-aminoacylase to act on an acylated amino acid to obtain a D-amino acid (see JP-A Hei 11-113592 ).
- the content of the D-amino acid material in the skin cosmetic composition of the invention is preferably from 0.1 to 5.0% by mass based on the total amount of the cosmetic composition.
- a homopolymer, a copolymer, or a crosspolymer including, as a constituent unit, one or more selected from 2-acrylamido-2-methylpropanesulfonic acid (hereinafter also abbreviated as "AMPS”), acrylic acid, and derivatives thereof, which is used as the ingredient (B) in the invention.
- AMPS 2-acrylamido-2-methylpropanesulfonic acid
- acrylic acid and derivatives thereof
- Examples of the ingredient (B) used in the invention include a vinylpyrrolidone/2-acrylamido-2-methylpropanesulfonic acid (salt) copolymer, a dimethylacrylamide/2-acrylamido-2-methylpropanesulfonic acid (salt) copolymer, an acrylamide/2-acrylamido-2-methylpropanesulfonic acid copolymer, a methylenebisacrylamide-crosslinked dimethylacrylamide/2-acrylamido-2-methylpropanesulfonic acid crosspolymer, a mixture of polyacrylamide and poly (sodium acrylate), a sodium acrylate/2-acrylamido-2-methylpropanesulfonic acid copolymer, a hydroxyethyl acrylate/2-acrylamido-2-methylpropanesulfonic acid (salt) copolymer, poly(ammonium acrylate), a polyacrylamide/ammonium acrylate copolymer, and an acrylamide/sodium acryl
- the salt include an alkali metal salt (such as a calcium salt or a magnesium salt), an ammonium salt, and an organic amine salt (such as a monoethanolamine salt, a diethanolamine salt, or a triethanolamine salt).
- alkali metal salt such as a calcium salt or a magnesium salt
- ammonium salt such as sodium bicarbonate
- organic amine salt such as a monoethanolamine salt, a diethanolamine salt, or a triethanolamine salt
- ingredients may be synthetic products or commercially available products.
- examples include ARISTOFLEX AVC (manufactured by Clariant), which corresponds to a vinylpyrrolidone/2-acrylamido-2-methylpropanesulfonic acid (salt) copolymer, SIMULGEL EG (manufactured by SEPIC) and SIMULGEL EPG (manufactured by SEPIC), which each correspond to a sodium acrylate/2-acrylamido-2-methylpropanesulfonic acid (salt) copolymer, SIMULGEL 600 (manufactured by SEPIC) , which corresponds to an acrylamide/2-acrylamido-2-methylpropanesulfonic acid sodium salt copolymer, SEPIGEL 305 (manufactured by SEPIC) and SEPIGEL 501 (manufactured by SEPIC), which each correspond to an acrylamide/2-acrylamido-2-methylpropanesulfonic acid (salt)
- the content of the ingredient (B) in the skin cosmetic composition of the invention is preferably from 0.1 to 2.0% by mass, more preferably from 0.3 to 1.5% by mass, based on the total amount of the cosmetic composition. If the content is less than 0.1% by mass, a phenomenon such separation, oil floating, demulsification, or aggregation can be more likely to occur, which is not preferred in view of stability. On the other hand, the ingredient (B) added at a content of more than 2.0% by mass will no longer increase the effects of the invention and may contrarily produce a sticky feeling.
- the ingredient (C) used in the invention may be any ester oil with an IOB value of 0.2 to 0.6.
- the content of the ingredient (C) in the skin cosmetic composition of the invention is preferably from 1.0 to 15.0% by mass, more preferably from 3.0 to 12.0% by mass, based on the total amount of the cosmetic composition. If the content is less than 1.0% by mass, an advantageous effect of the invention, specifically, suppression of stickiness and production of a penetrating feeling may be insufficient.
- the ingredient (D) used in the invention may be glycerin commonly used in cosmetics, which may be a synthetic product or a commercially-available product.
- glycerin which is known to be highly effective in improving the skin but to be sticky, may be used at a content of as relatively high as 5.0 to 15.0% by mass based on the total amount of the cosmetic composition, so that the effect of improving the skin can be reliably obtained.
- the ingredients (A), (B), and (C) are mixed with it, so that a non-sticky cosmetic composition can be obtained.
- the oil-in-water type emulsion skin cosmetic composition of the invention may be produced by adding a water-phase component to an oil-phase component and stirring and mixing them by a conventional method with a homogenizer or the like.
- the water-phase component may contain various water-soluble ingredients in water or in an aqueous phase composed mainly of water.
- the content of the water-phase component is preferably from 50.0 to 80.0% by mass based on the total amount of the oil-in-water emulsion skin cosmetic composition. If the water-phase component is less than 50.0% by mass, heavy feeling or stickiness may occur. On the other hand, if it is more than 80.0% by mass, the cosmetic composition will be light but not moist, so that a high skin improving effect, an advantageous effect of the invention, can be sometimes hard to obtain.
- ingredients that can be usually added to emulsion cosmetics may be appropriately added to the oil-in-water type emulsion cosmetic composition of the invention as long as the effects of the invention are not impaired.
- examples of such other ingredients include, but are not limited to, ultraviolet absorbers, ultraviolet scattering agents, waxes, hydrocarbon oils, fatty acid esters, silicone oils, polyhydric alcohols, water-soluble polymers, higher alcohols, higher fatty acids, and active agents.
- ultraviolet absorbers examples include p-aminobenzoic acid, octyl-p-methoxycinnamate (2-ethylhexyl-p-methoxycinnamate), glyceryl mono-2-ethylhexanoyl-di-p-methoxycinnamate, methyl bis(trimethylsiloxane)silylisopentyl trimethoxycinnamate, and other cinnamic acid derivative ultraviolet absorbers, 2,2'-hydroxy-5-methylphenylbenzotriazole, 2-(2'-hydroxy-5'-t-octylphenyl)benzotriazole, 2-(2'-hydroxy-5'-methylphenyl benzotriazole, 4-methoxy-4'-t-butyldibenzoylmethane, 5-(3,3-dimethyl-2-norbornylidene)-3-pentan-2-one, bis-ethylhexyloxyphenol-meth
- ultraviolet scattering agents include fine particles with an average particle size of 10 to 100 nm, such as fine particles of titanium oxide, fine particles of zinc oxide, fine particles of iron oxide, and fine particles of cerium oxide.
- Ultraviolet scattering agents hydrophobized by a silicone treatment with methyl hydrogen polysiloxane or a silane coupling agent, by a metal soap treatment, by a fluorine treatment with a perfluoroalkylphosphoric acid diethanolamine salt or perfluoroalkylsilane, by a dextrin fatty acid ester treatment, or by other methods may also be added as needed depending on the dosage form.
- waxes examples include beeswax, candelilla wax, carnauba wax, lanolin, liquid lanolin, and jojoba wax.
- hydrocarbon oils include liquid paraffin, ozocerite, squalane, pristane, paraffin, ceresin, squalene, petrolatum, microcrystalline wax, polyethylene wax, and Fischer-Tropsch wax.
- fatty acid esters include cetyl palmitate, cholesteryl stearate, and beeswax fatty acid 2-octyldodecyl ester.
- silicone oils include chain polysiloxanes (e.g., dimethylpolysiloxane, methylphenylpolysiloxane, and diphenylpolysiloxane); cyclic polysiloxanes (e.g., decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane), silicone resins forming a three-dimensional network structure, silicone rubbers with an average molecular weight of 200,000 or more, and various modified polysiloxanes (such as amino-modified polysiloxanes, polyether-modified polysiloxanes, alkyl-modified polysiloxanes, and fluorine-modified polysiloxanes).
- chain polysiloxanes e.g., dimethylpolysiloxane, methylphenylpolysiloxane, and diphenylpolysiloxane
- cyclic polysiloxanes e.g., de
- polyhydric alcohols examples include polyethylene glycol, glycerin, diglycerin, 1,3-butylene glycol, erythritol, sorbitol, xylitol, maltitol, 1,2-pentanediol, and hexylene glycol.
- water-soluble polymers examples include carrageenan, pectin, mannan, curdlan, chondroitin sulfate, starch, glycogen, gum arabic, sodium hyaluronate, tragacanth gum, xanthan gum, mucoitin sulfuric acid, hydroxyethyl guar gum, carboxymethyl guar gum, guar gum, dextran, keratosulfate, locust bean gum, succinoglucan, chitin, chitosan, carboxymethyl chitin, and agar.
- higher alcohols include hexyl alcohol, octyl alcohol, cetyl alcohol, stearyl alcohol, ceryl alcohol, behenyl alcohol, triacontyl alcohol, cerakyl alcohol, and batyl alcohol.
- higher fatty acids include lauric acid, myristic acid, palmitic acid, stearic acid, and behenic acid.
- L-ascorbic acid derivatives include L-ascorbic acid monoalkyl esters such as L-ascorbic acid monostearate, L-ascorbic acid monopalmitate, and L-ascorbic acid monooleate; L-ascorbic acid monoesters such as L-ascorbic acid monophosphate and L-ascorbic acid-2-sulfate; L-ascorbic acid dialkyl esters such as L-ascorbic acid distearate, L-ascorbic acid dipalmitate, and L-ascorbic acid dioleate; L-ascorbic acid trialkyl esters such as L-ascorbic acid tristearate, L-ascorbic acid tripalmitate, and L
- tranexamic acid derivatives include tranexamic acid dimers (e.g., trans-4-(trans-aminomethylcyclohexanecarbonyl)aminomethylcy clohexanecarboxylic acid hydrochloride), tranexamic acid hydroquinone esters (e.g., 4-(trans-aminomethylcyclohexanecarboxylic acid 4'-hydroxyphenyl ester), tranexamic acid gentisic acid esters (e.g., 2-(trans-4-aminomethylcyclohexylcarbonyloxy)-5-hydroxybenzo ic acid), and tranexamic acid amides (e.g., trans-4-aminomethylcyclohexanecarboxylic acid methylamide, trans-4-(p-methoxybenzoyl)aminomethylcyclohexanecarboxylic acid, and trans-4-guanidinomethylcyclohexanecarboxylic acid).
- Alkoxysalicylic acid is a salicylic acid derivative in which the hydrogen atom at 3, 4, or 5 position of salicylic acid is replaced by an alkoxy group.
- the alkoxy group as a substituent is preferably any one of methoxy, ethoxy, propoxy, isopropoxy, butoxy, and isobutoxy groups, more preferably a methoxy group or an ethoxy group.
- alkoxysalicylic acid and a derivative thereof are each preferably used in the form of a salt.
- the salts of drugs include, but are not limited to, alkali metal or alkaline-earth metal salts such as sodium salts, potassium salts, and calcium salts, and other salts such as ammonium salts and amino acid salts.
- ingredients that may be added also include vitamin A, vitamin A derivatives such as vitamin A palmitate and vitamin A acetate, vitamin B6 hydrochloride, vitamin B 6 tripalmitate, vitamin B 6 dioctanoate, vitamin B 2 and derivatives thereof, vitamin B 12 , vitamin B 15 and derivatives thereof, and other vitamin B materials, ⁇ -tocopherol, ⁇ -tocopherol, vitamin E acetate, and other vitamin E materials, vitamin D materials, vitamin H, pantothenic acid, pantethine, and other vitamins; ⁇ -oryzanol, allantoin, glycyrrhizinic acid (salt), glycyrrhetinic acid, stearyl glycyrrhetinate, hinokitiol, bisabolol, eukalypton, thymol, inositol, saikosaponin, carrot saponin, sponge gourd saponin, mukurossi peel saponin, and
- ingredients also include lower alcohols such as ethanol; antioxidants such as butylhydroxytoluene, ⁇ -tocopherol, and phytin; preservatives such as benzoic acid, salicylic acid, sorbic acid, alkyl p-oxybenzoate, phenoxyethanol, hexachlorophene, ands-polylysine; and organic or inorganic acids such as citric acid, lactic acid, and hexametaphosphoric acid, and salts thereof.
- lower alcohols such as ethanol
- antioxidants such as butylhydroxytoluene, ⁇ -tocopherol, and phytin
- preservatives such as benzoic acid, salicylic acid, sorbic acid, alkyl p-oxybenzoate, phenoxyethanol, hexachlorophene, ands-polylysine
- organic or inorganic acids such as citric acid, lactic acid, and hexametaphosphoric acid, and salts thereof
- oils-in-water type emulsion skin cosmetic composition of the invention include, but are not limited to, skin milk, skin cream, hair cream, liquid foundation, eye liner, mascara, eye shadow, and any other milky or creamy products.
- a panel of female experts carried out an actual use test to evaluate speadability on skin and made evaluations according to the criteria below.
- a panel of female experts carried out an actual use test to evaluate stickiness and made evaluations according to the criteria below.
- a panel of female experts carried out an actual use test to evaluate lightness and made evaluations according to the criteria below.
- a panel of female experts carried out an actual use test to evaluate skin resilience and made evaluations according to the criteria below.
- a panel of female experts carried out an actual use test to evaluate the effect of moisturizing the skin and made evaluations according to the criteria below.
- oil-in-water type emulsion skin cosmetic creams were prepared by a conventional method.
- the resulting compositions were evaluated for stability, texture, and skin improving effect according to the methods and criteria described above.
- "vinylpyrrolidone/sodium 2-acrylamido-methylpropanesulfonate copolymer” used as the “ingredient (B)” was "ARISTOFLEX AVC” (manufactured by CLARIANT).
- Example 1 Ingredients Example 1 2 3 4 5 6 7 (1) Ion-exchanged water Balance Balance Balance Balance Balance Balance Balance Balance Balance Balance (2) D-alanine [ingredient (A)] 0.1 3.0 5.0 0.1 3.0 3.0 3.0 (3) Glycerin [ingredient (D)] 5.0 10.0 15.0 10.0 5.0 10.0 10.0 (4) 1,3-butylene glycol 3.0 3.0 3.0 3.0 3.0 3.0 (5) Vinylpyrrolidone/sodium 2-acrylamido-methylpropanesulfonate copolymer [ingredient (B)] 0.1 1.0 2.0 1.0 1.0 0.1 1.0 (5') Carboxyvinyl polymer - - - - - - - (6) Self-emulsitying glyceryl monostearate 3.0 3.0 3.0 3.0 3.0 3.0 (7) PEG-100 stearate 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 (8) Stearic acid 0.1 0.1 0.1 0.1 0.1 0.1
- Tables 1 and 2 show that Examples 1 to 7 according to the invention are excellent in stability, texture, and skin improving effect. In contrast, not all of stability, texture, and skin improving effect are satisfactory with respect to Comparative Examples 1 to 6, which do not satisfy the requirements of the invention. Specifically, Comparative Examples 1 to 3 and 6 lack any of the ingredients (A) , (B) , (C) , and (D) . Comparative Example 1 not containing the ingredient (A) is sticky and lacks a skin moisturizing effect. Comparative Example 2 not containing the ingredient (B) particularly has a problem with stability. Comparative Example 3 not containing the ingredient (C) is significantly inferior in texture such as spreadability on skin, stickiness, or lightness. Comparative Example 6 not containing the ingredient (D) does not produce a skin improving effect such as a skin moisturizing effect.
- Comparative Example 4 containing another thickener (carboxyvinyl polymer) instead of the ingredient (B) is insufficient in texture with respect to stickiness, lightness, etc. and insufficient in skin improving effect.
- Comparative Example 5 containing squalane with an IOB of 0 instead of the ingredient (C) is sticky and lacks spreadability on skin and lightness, although it makes the skin resilient and moisturized.
- ingredients (1) to (8) were uniformly mixed and dissolved at 70°C (oil phase) .
- ingredients (9) to (18) were uniformly mixed and dissolved at 70°C (aqueous phase) .
- the oil phase was gradually added to the aqueous phase kept at 70°C, the mixture was emulsified with a homomixer. After the emulsification was completed, the emulsion was rapidly cooled to 40°C or less to give the desired anti-aging cream.
- the resulting cream was evaluated in the same manner as described above for Examples 1 to 7. As a result, the cream had good texture (the evaluation was ⁇ with respect to all of skin spreadability, stickiness, and lightness) , a moisturizing effect, light spreadability, and a moist feeling with lightness when applied to the skin, and also had good stability (the stability was evaluated "O").
- ingredients (1) to (9) were uniformly mixed and dissolved at 70°C (oil phase).
- ingredients (10) to (16) were uniformly mixed and dissolved at 70°C (aqueous phase) . While the oil phase was gradually added to the aqueous phase kept at 70°C, the mixture was emulsified with a homomixer. After the emulsification was completed, the emulsion was rapidly cooled to 40°C or less to give the desired O/W emulsion type sunscreen.
- the resulting sunscreen was evaluated in the same manner as Examples 1 to 7. As a result, the sunscreen had good texture (the evaluation was ⁇ with respect to all of skin spreadability, stickiness, and lightness), a moisturizing effect, light spreadability, and a moist feeling with lightness when applied to the skin, and also had good stability (the stability was evaluated "O") .
- ingredients (1) to (7) were uniformly mixed and dissolved at 70°C (oil phase).
- ingredients (8) to (19) were uniformly mixed and dissolved at 70°C (aqueous phase). While the oil phase was gradually added to the aqueous phase kept at 70°C, the mixture was emulsified with a homomixer. After the emulsification was completed, the emulsion was rapidly cooled to 40°C or less to give the desired whitening cream.
- the resulting whitening cream was evaluated in the same manner as Examples 1 to 7.
- the cream had good texture (the evaluation was ⁇ with respect to all of skin spreadability, stickiness, and lightness), a moisturizing effect, light spreadability, and a moist feeling with lightness when applied to the skin, and also had good stability (the stability was evaluated "O").
- ingredients (1) to (8) were uniformly mixed and dissolved at 70°C (oil phase).
- ingredients (9) to (20) were uniformly mixed and dissolved at 70°C (aqueous phase). While the oil phase was gradually added to the aqueous phase kept at 70°C, the mixture was emulsified with a homomixer. After the emulsification was completed, the emulsion was rapidly cooled to 40°C or less to give the desired whitening cream.
- the resulting whitening cream was evaluated in the same manner as Examples 1 to 7.
- the cream had good texture (the evaluation was ⁇ with respect to all of skin spreadability, stickiness, and lightness), a moisturizing effect, light spreadability, and a moist feeling with lightness when applied to the skin, and also had good stability (the stability was evaluated "O").
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
- The invention relates to an oil-in-water type emulsion skin cosmetic composition having good texture and stability. More specifically, the invention relates to an oil-in-water type emulsion skin cosmetic composition having light spreadability on skin, no stickiness, lightness, a good feeling as an active ingredient effectively penetrates into the skin (good penetrating feeling), and high stability over time.
- Glycerin is known as a cosmetic ingredient having a high moisturizing effect and a high skin improving effect such as a high skin roughness reducing effect. To produce such a high skin improving effect significantly, glycerin is often added at a content of 5.0% by mass or more. Particularly, skin cosmetics with high glycerin content can produce high skin improving effect but may have the disadvantage in use that as the content increases, dewy feeling or feeling as an active ingredient penetrates into the skin disappears, and stickiness appears.
- In recent years, there have been attempts, such as the addition of fatty acid glycerin ester, the addition of specific water-soluble solid silicone, and the addition of organosiloxane elastomer spherical particles, to reduce stickiness caused by the addition of glycerin and to obtain a light feeling (see Patent Documents 1 to 3).
- However, these conventional techniques tend to reduce the skin improving effect of glycerin in conflict with a certain stickiness reducing effect produced by the addition of the above additive.
- On the other hand, acrylamide thickeners, which are used as cosmetic thickeners, provide good texture such as good compatibility to the skin or good spreadability (see for example Patent Documents 4 and 5). Such acrylamide thickeners are useful as an alternative to carboxyvinyl polymer, xanthan gum, or hydroxyethyl cellulose, which is traditionally used as a cosmetic thickener in many cases. However, when glycerin is added at a high concentration to provide a skin improving effect, a problem also occurs in which good texture of acrylamide thickeners is lost and it becomes impossible to reduce the glycerin-induced stickiness.
-
- Patent Document 1:
JP-A Hei 11-246329 - Patent Document 2:
JP-A 2000-191428 - Patent Document 3:
JP-A 2002-356416 - Patent Document 4:
JP-A Hei 10-67685 - Patent Document 5:
JP-A 2001-114641 - It is therefore an object of the invention to solve the conventional problems and to provide an oil-in-water type emulsion skin cosmetic composition that has light spreadability on skin, no stickiness, and a good penetrating feeling as an active ingredient effectively penetrates into the skin, provides moisture, and is moist even in a system with a high glycerin content or in a system used in combination with an acrylamide thickener, and also allows glycerin to produce a high skin improving effect.
- As a result of earnest studies to solve the problems, the present inventors have accomplished the invention based on the finding that even in a system with a high glycerin content, an oil-in-water type emulsion skin cosmetic composition containing (A) a D-amino acid or a derivative or salt thereof, (B) a homopolymer, a copolymer, or a crosspolymer including, as a constituent unit, one or more selected from 2-acrylamido-2-methylpropanesulfonic acid, acrylic acid, and derivatives thereof, (C) an ester oil with an IOB value of 0.2 to 0.6, and (D) glycerin is compatible to the skin and not sticky during use, and can reliably produce a skin improving effect.
- According to the invention, there is provided an oil-in-water type emulsion skin cosmetic composition that has light spreadability on skin, no stickiness, and a good penetrating feeling when an active ingredient penetrates the skin, provides moisture, and is moist even in a system with a high glycerin content, and also allows glycerin to produce a high skin improving effect.
- Hereinafter, the invention is described in detail.
The skin cosmetic composition of the invention essentially contains a D-amino acid or a derivative or salt thereof (ingredient (A), hereinafter also abbreviated as "D-amino acid maternal"). As used herein, the term "D-amino acid or a derivative or salt thereof (D-amino acid material)" means a D-amino acid, a derivative thereof, a salt thereof, or a mixture thereof. - It is well known that amino acids can exist in L-form or D-form which are optical isomers and natural proteins are composed of L-amino acids bonded together by peptide bonds. It has been considered that except for some cases such as bacterial cell walls, only L-amino acids exist in mammals including human and only L-amino acids are used in living bodies. Conventionally, therefore, academic or industrial focus and research have been dominantly on L-amino acids.
Exceptional cases where D-amino acids are used include (1) cases where D-amino acids are used as raw materials for antibiotics to be produced by bacteria and (2) cases where food additives contain a mixture of L- and D-amino acids in order to avoid the cost required to isolate the L-amino acid from the mixture (racemic mixture) containing equal amounts of the Land D-amino acids synthesized chemically. - Recently, it has been found that even in the human body, D-aspartic acid (D-Asp), which does not occur naturally, increases with age in the ocular lens, brain, or skin, and the relationship between it and the development of cataract or Alzheimer's disease has begun to be discussed (Tadatoshi Kinouchi et al. "proteins, Nucleic Acids, and Enzymes" (in Japanese) Vol. 50, No. 5 (2005), 453-560). Also in the skin, accumulation of D-Asp has been found to be caused by aging or ultraviolet irradiation, and it has been proposed that D-Asp be used as a molecular marker for detecting skin damage caused by aging or ultraviolet rays (Noriko Fujii, Annual Report of Cosmetology (in Japanese) , No.
13 (2005
Under the above circumstances, the invention is characterized in that a D-amino acid, which has not been conventionally added to cosmetics, especially skin cosmetics, is added as an essential ingredient. - The D-amino acid material (ingredient (A)) used in the invention may be of any type as long as it is in the D-form. Preferably, the D-amino acid material itself can be effective in improving the skin. Examples include D-aspartic acid, which can have an antioxidant effect and a collagen production promoting effect, D-alanine, which can have a laminin 332 production promoting effect and a collagen production promoting effect, D-glutamic acid, which can have a barrier recovery function, a wrinkle formation reducing effect, and a skin roughness reducing effect, D-serine, which can have an ultraviolet damage reducing effect, D-hydroxyproline, which can have a laminin 332 production promoting effect, D-cysteine, which can have an ultraviolet damage reducing effect, D-methionine and D-proline, which can have an ultraviolet damage reducing effect, and D-hydroxyproline, which can have a melanin production inhibiting effect.
- The D-amino acid material used in the invention may be a synthetic product or a commercially available product.
For example, a known method for producing a D-amino acid includes allowing bacterial D-aminoacylase to act on an acylated amino acid to obtain a D-amino acid (seeJP-A Hei 11-113592
The content of the D-amino acid material in the skin cosmetic composition of the invention is preferably from 0.1 to 5.0% by mass based on the total amount of the cosmetic composition. - Next, a detailed description is given of a homopolymer, a copolymer, or a crosspolymer including, as a constituent unit, one or more selected from 2-acrylamido-2-methylpropanesulfonic acid (hereinafter also abbreviated as "AMPS"), acrylic acid, and derivatives thereof, which is used as the ingredient (B) in the invention.
- Examples of the ingredient (B) used in the invention include a vinylpyrrolidone/2-acrylamido-2-methylpropanesulfonic acid (salt) copolymer, a dimethylacrylamide/2-acrylamido-2-methylpropanesulfonic acid (salt) copolymer, an acrylamide/2-acrylamido-2-methylpropanesulfonic acid copolymer, a methylenebisacrylamide-crosslinked dimethylacrylamide/2-acrylamido-2-methylpropanesulfonic acid crosspolymer, a mixture of polyacrylamide and poly (sodium acrylate), a sodium acrylate/2-acrylamido-2-methylpropanesulfonic acid copolymer, a hydroxyethyl acrylate/2-acrylamido-2-methylpropanesulfonic acid (salt) copolymer, poly(ammonium acrylate), a polyacrylamide/ammonium acrylate copolymer, and an acrylamide/sodium acrylate copolymer. It will be understood that these are non-limiting examples.
In the above polymers, preferred examples of the salt include an alkali metal salt (such as a calcium salt or a magnesium salt), an ammonium salt, and an organic amine salt (such as a monoethanolamine salt, a diethanolamine salt, or a triethanolamine salt). One or more of these (B) ingredients may be used. - These (B) ingredients may be synthetic products or commercially available products. Examples include ARISTOFLEX AVC (manufactured by Clariant), which corresponds to a vinylpyrrolidone/2-acrylamido-2-methylpropanesulfonic acid (salt) copolymer, SIMULGEL EG (manufactured by SEPIC) and SIMULGEL EPG (manufactured by SEPIC), which each correspond to a sodium acrylate/2-acrylamido-2-methylpropanesulfonic acid (salt) copolymer, SIMULGEL 600 (manufactured by SEPIC) , which corresponds to an acrylamide/2-acrylamido-2-methylpropanesulfonic acid sodium salt copolymer, SEPIGEL 305 (manufactured by SEPIC) and SEPIGEL 501 (manufactured by SEPIC), which each correspond to an acrylamide/2-acrylamido-2-methylpropanesulfonic acid (salt) copolymer, Hostacerin AMPS (manufactured by Clariant) and SIMULGEL 800 (manufactured by SEPIC), which each correspond to a homopolymer of 2-acrylamido-2-methylpropanesulfonic acid sodium salt, and SU-POLYMER G-1 (manufactured by TOHO Chemical Industry Co., Ltd.), which corresponds to a dimethylacrylamide/2-acrylamido-2-methylpropanesulfonic acid copolymer.
- The content of the ingredient (B) in the skin cosmetic composition of the invention is preferably from 0.1 to 2.0% by mass, more preferably from 0.3 to 1.5% by mass, based on the total amount of the cosmetic composition. If the content is less than 0.1% by mass, a phenomenon such separation, oil floating, demulsification, or aggregation can be more likely to occur, which is not preferred in view of stability. On the other hand, the ingredient (B) added at a content of more than 2.0% by mass will no longer increase the effects of the invention and may contrarily produce a sticky feeling.
- Next, a detailed description is given of an ester oil with an IOB value of 0.2 to 0.6, the ingredient (C), used in the invention.
The ingredient (C) used in the invention may be any ester oil with an IOB value of 0.2 to 0.6. Examples include tripropylene glycol dineopentanoate (IOB=0.52), isodecyl benzoate (IOB=0.23), propylene glycol dicaprylate (IOB=0.32), isononyl isononanoate (IOB=0.2), cetyl 2-ethylhexanoate (IOB=0.52), glyceryl tri-2-ethylhexanoate (IOB=0.36), isodecyl neopentanoate (IOB=0.22), 2-ethylhexyl 2-ethylhexanoate (IOB=0.2), pentaerythritol tetra-2-ethylhexanoate (IOB=0.35), di-2-ethylhexyl succinate (IOB=0.32), and 2-ethylhexyl isononanoate (IOB=0.2). - One or more of these ester oils may be used.
Particularly in view of texture, the content of the ingredient (C) in the skin cosmetic composition of the invention is preferably from 1.0 to 15.0% by mass, more preferably from 3.0 to 12.0% by mass, based on the total amount of the cosmetic composition. If the content is less than 1.0% by mass, an advantageous effect of the invention, specifically, suppression of stickiness and production of a penetrating feeling may be insufficient. - Next, a description is given of glycerin, the ingredient (D), used in the invention.
The ingredient (D) used in the invention may be glycerin commonly used in cosmetics, which may be a synthetic product or a commercially-available product.
In the invention, glycerin (the ingredient (D)), which is known to be highly effective in improving the skin but to be sticky, may be used at a content of as relatively high as 5.0 to 15.0% by mass based on the total amount of the cosmetic composition, so that the effect of improving the skin can be reliably obtained. On the other hand, the ingredients (A), (B), and (C) are mixed with it, so that a non-sticky cosmetic composition can be obtained. - The oil-in-water type emulsion skin cosmetic composition of the invention may be produced by adding a water-phase component to an oil-phase component and stirring and mixing them by a conventional method with a homogenizer or the like. The water-phase component may contain various water-soluble ingredients in water or in an aqueous phase composed mainly of water. The content of the water-phase component is preferably from 50.0 to 80.0% by mass based on the total amount of the oil-in-water emulsion skin cosmetic composition. If the water-phase component is less than 50.0% by mass, heavy feeling or stickiness may occur. On the other hand, if it is more than 80.0% by mass, the cosmetic composition will be light but not moist, so that a high skin improving effect, an advantageous effect of the invention, can be sometimes hard to obtain.
- Besides the above essential ingredients, other ingredients that can be usually added to emulsion cosmetics may be appropriately added to the oil-in-water type emulsion cosmetic composition of the invention as long as the effects of the invention are not impaired.
Examples of such other ingredients include, but are not limited to, ultraviolet absorbers, ultraviolet scattering agents, waxes, hydrocarbon oils, fatty acid esters, silicone oils, polyhydric alcohols, water-soluble polymers, higher alcohols, higher fatty acids, and active agents. - Examples of ultraviolet absorbers include p-aminobenzoic acid, octyl-p-methoxycinnamate (2-ethylhexyl-p-methoxycinnamate), glyceryl mono-2-ethylhexanoyl-di-p-methoxycinnamate, methyl bis(trimethylsiloxane)silylisopentyl trimethoxycinnamate, and other cinnamic acid derivative ultraviolet absorbers, 2,2'-hydroxy-5-methylphenylbenzotriazole, 2-(2'-hydroxy-5'-t-octylphenyl)benzotriazole, 2-(2'-hydroxy-5'-methylphenyl benzotriazole, 4-methoxy-4'-t-butyldibenzoylmethane, 5-(3,3-dimethyl-2-norbornylidene)-3-pentan-2-one, bis-ethylhexyloxyphenol-methoxyphenyl-triazine, 2,4,6-tris[4-(2-ethylhexyloxycarbonyl)anilino]1,3,5-triazin e, dimorpholinopyridazinone, and 2-ethylhexyl-2-cyano-3,3-diphenylacrylate.
- Examples of ultraviolet scattering agents include fine particles with an average particle size of 10 to 100 nm, such as fine particles of titanium oxide, fine particles of zinc oxide, fine particles of iron oxide, and fine particles of cerium oxide.
Ultraviolet scattering agents hydrophobized by a silicone treatment with methyl hydrogen polysiloxane or a silane coupling agent, by a metal soap treatment, by a fluorine treatment with a perfluoroalkylphosphoric acid diethanolamine salt or perfluoroalkylsilane, by a dextrin fatty acid ester treatment, or by other methods may also be added as needed depending on the dosage form. - Examples of waxes include beeswax, candelilla wax, carnauba wax, lanolin, liquid lanolin, and jojoba wax.
Examples of hydrocarbon oils include liquid paraffin, ozocerite, squalane, pristane, paraffin, ceresin, squalene, petrolatum, microcrystalline wax, polyethylene wax, and Fischer-Tropsch wax.
Examples of fatty acid esters include cetyl palmitate, cholesteryl stearate, and beeswax fatty acid 2-octyldodecyl ester. - Examples of silicone oils include chain polysiloxanes (e.g., dimethylpolysiloxane, methylphenylpolysiloxane, and diphenylpolysiloxane); cyclic polysiloxanes (e.g., decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane), silicone resins forming a three-dimensional network structure, silicone rubbers with an average molecular weight of 200,000 or more, and various modified polysiloxanes (such as amino-modified polysiloxanes, polyether-modified polysiloxanes, alkyl-modified polysiloxanes, and fluorine-modified polysiloxanes).
- Examples of polyhydric alcohols include polyethylene glycol, glycerin, diglycerin, 1,3-butylene glycol, erythritol, sorbitol, xylitol, maltitol, 1,2-pentanediol, and hexylene glycol.
Examples of water-soluble polymers include carrageenan, pectin, mannan, curdlan, chondroitin sulfate, starch, glycogen, gum arabic, sodium hyaluronate, tragacanth gum, xanthan gum, mucoitin sulfuric acid, hydroxyethyl guar gum, carboxymethyl guar gum, guar gum, dextran, keratosulfate, locust bean gum, succinoglucan, chitin, chitosan, carboxymethyl chitin, and agar. - Examples of higher alcohols include hexyl alcohol, octyl alcohol, cetyl alcohol, stearyl alcohol, ceryl alcohol, behenyl alcohol, triacontyl alcohol, cerakyl alcohol, and batyl alcohol.
Examples of higher fatty acids include lauric acid, myristic acid, palmitic acid, stearic acid, and behenic acid. - Example of active agents include salts of L-ascorbic acid and derivatives thereof, salts of tranexamic acid and derivatives thereof, salts of alkoxysalicylic acid and derivatives thereof, and salts of glutathione and derivatives thereof. More specifically, L-ascorbic acid derivatives include L-ascorbic acid monoalkyl esters such as L-ascorbic acid monostearate, L-ascorbic acid monopalmitate, and L-ascorbic acid monooleate; L-ascorbic acid monoesters such as L-ascorbic acid monophosphate and L-ascorbic acid-2-sulfate; L-ascorbic acid dialkyl esters such as L-ascorbic acid distearate, L-ascorbic acid dipalmitate, and L-ascorbic acid dioleate; L-ascorbic acid trialkyl esters such as L-ascorbic acid tristearate, L-ascorbic acid tripalmitate, and L-ascorbic acid trioleate; L-ascorbic acid triesters such as L-ascorbic acid triphosphate; and L-ascorbic acid glucosides such as L-ascorbic acid 2-glucoside. In the invention, L-ascorbic acid, L-ascorbic acid phosphate, L-ascorbic acid-2-sulfate, and L-ascorbic acid 2-glucoside are each preferably used in the form of a salt.
- Examples of tranexamic acid derivatives include tranexamic acid dimers (e.g., trans-4-(trans-aminomethylcyclohexanecarbonyl)aminomethylcy clohexanecarboxylic acid hydrochloride), tranexamic acid hydroquinone esters (e.g., 4-(trans-aminomethylcyclohexanecarboxylic acid 4'-hydroxyphenyl ester), tranexamic acid gentisic acid esters (e.g., 2-(trans-4-aminomethylcyclohexylcarbonyloxy)-5-hydroxybenzo ic acid), and tranexamic acid amides (e.g., trans-4-aminomethylcyclohexanecarboxylic acid methylamide, trans-4-(p-methoxybenzoyl)aminomethylcyclohexanecarboxylic acid, and trans-4-guanidinomethylcyclohexanecarboxylic acid). In the invention, tranexamic acid or a tranexamic acid derivative is preferably used in the form of a salt.
- Alkoxysalicylic acid is a salicylic acid derivative in which the hydrogen atom at 3, 4, or 5 position of salicylic acid is replaced by an alkoxy group. The alkoxy group as a substituent is preferably any one of methoxy, ethoxy, propoxy, isopropoxy, butoxy, and isobutoxy groups, more preferably a methoxy group or an ethoxy group. Examples of such a compound include 3-methoxysalicylic acid, 3-ethoxysalicylic acid, 4-methoxysalicylic acid, 4-ethoxysalicylic acid, 4-propoxysalicylic acid, 4-isopropoxysalicylic acid, 4-butoxysalicylic acid, 5-methoxysalicylic acid, 5-ethoxysalicylic acid, and 5-propoxysalicylic acid. In the invention, alkoxysalicylic acid and a derivative thereof (such as an ester) are each preferably used in the form of a salt.
Examples of the salts of drugs include, but are not limited to, alkali metal or alkaline-earth metal salts such as sodium salts, potassium salts, and calcium salts, and other salts such as ammonium salts and amino acid salts. - Other ingredients that may be added also include vitamin A, vitamin A derivatives such as vitamin A palmitate and vitamin A acetate, vitamin B6 hydrochloride, vitamin B6 tripalmitate, vitamin B6 dioctanoate, vitamin B2 and derivatives thereof, vitamin B12, vitamin B15 and derivatives thereof, and other vitamin B materials, α-tocopherol, β-tocopherol, vitamin E acetate, and other vitamin E materials, vitamin D materials, vitamin H, pantothenic acid, pantethine, and other vitamins; γ-oryzanol, allantoin, glycyrrhizinic acid (salt), glycyrrhetinic acid, stearyl glycyrrhetinate, hinokitiol, bisabolol, eukalypton, thymol, inositol, saikosaponin, carrot saponin, sponge gourd saponin, mukurossi peel saponin, and other saponins, pantothenyl ethyl ether, arbutin, cepharanthine, and other various medicines, extracts of plants such as curly dock, sophora, Nuphar, orange, sage, yarrow, mallow, swertia herb, thyme, Japanese angelica root, spruce, white birch, horsetail, sponge gourd, horse chestnut, saxifrage, scutellaria root, arnica, lily, mugwort, peony, aloe, gardenia, and cherry leaf, and β-carotene and other colorants.
- Other ingredients also include lower alcohols such as ethanol; antioxidants such as butylhydroxytoluene, δ-tocopherol, and phytin; preservatives such as benzoic acid, salicylic acid, sorbic acid, alkyl p-oxybenzoate, phenoxyethanol, hexachlorophene, ands-polylysine; and organic or inorganic acids such as citric acid, lactic acid, and hexametaphosphoric acid, and salts thereof.
- Examples of the form of the oil-in-water type emulsion skin cosmetic composition of the invention include, but are not limited to, skin milk, skin cream, hair cream, liquid foundation, eye liner, mascara, eye shadow, and any other milky or creamy products.
- Hereinafter, the invention is more specifically described with reference to examples, which however are not intended to limit the invention. All material content percentages are by mass unless otherwise specified.
First, a description is given of the evaluation methods used for the invention. - Samples were allowed to stand at 50°C for one month, and then their appearances were visually observed and evaluated according to the criteria below.
-
- O: Separation was not observed at all.
- Δ: Separation was hardly observed.
- ×: Separation in Liquid-phase (oil-phase or aqueous-phase) occurred.
- A panel of female experts (ten experts) carried out an actual use test to evaluate speadability on skin and made evaluations according to the criteria below.
-
- ⊙: All ten experts determined that spreading was light and smooth.
- O: Seven to nine experts determined that spreading was light and smooth.
- Δ: Three to six experts determined that spreading was light and smooth.
- ×: Zero to two experts determined that spreading was light and smooth.
- A panel of female experts (ten experts) carried out an actual use test to evaluate stickiness and made evaluations according to the criteria below.
-
- ⊙: All ten experts determined that there was a moist feeing with no stickiness.
- O: Seven to nine experts determined that there was a moist feeing with no stickiness.
- Δ: Three to six experts determined that there was a moist feeing with no stickiness.
- ×: Zero to two experts determined that there was a moist feeing with no stickiness.
- A panel of female experts (ten experts) carried out an actual use test to evaluate lightness and made evaluations according to the criteria below.
-
- ⊙: All ten experts determined that there was lightness.
- O: Seven to nine experts determined that there was lightness.
- ΔL: Three to six experts determined that there was lightness.
- ×: Zero to two experts determined that there was lightness.
- A panel of female experts (ten experts) carried out an actual use test to evaluate skin resilience and made evaluations according to the criteria below.
-
- ⊙: All ten experts determined that the skin became resilient.
- O: Seven to nine experts determined that the skin became resilient.
- Δ: Three to six experts determined that the skin became resilient.
- ×: Zero to two experts determined that the skin became resilient.
- A panel of female experts (ten experts) carried out an actual use test to evaluate the effect of moisturizing the skin and made evaluations according to the criteria below.
-
- ⊙: All ten experts determined that the skin was made moisturized.
- O: Seven to nine experts determined that the skin was made moisturized.
- Δ: Three to six experts determined that the skin was made moisturized.
- ×: Zero to two experts determined that the skin was made moisturized.
- According to the formulas shown in Tables 1 and 2 below, oil-in-water type emulsion skin cosmetic creams were prepared by a conventional method. The resulting compositions (samples) were evaluated for stability, texture, and skin improving effect according to the methods and criteria described above.
In Tables 1 and 2, "vinylpyrrolidone/sodium 2-acrylamido-methylpropanesulfonate copolymer" used as the "ingredient (B)" was "ARISTOFLEX AVC" (manufactured by CLARIANT). -
[Table 1] Ingredients Example 1 2 3 4 5 6 7 (1) Ion-exchanged water Balance Balance Balance Balance Balance Balance Balance (2) D-alanine [ingredient (A)] 0.1 3.0 5.0 0.1 3.0 3.0 3.0 (3) Glycerin [ingredient (D)] 5.0 10.0 15.0 10.0 5.0 10.0 10.0 (4) 1,3-butylene glycol 3.0 3.0 3.0 3.0 3.0 3.0 3.0 (5) Vinylpyrrolidone/sodium 2-acrylamido-methylpropanesulfonate copolymer [ingredient (B)] 0.1 1.0 2.0 1.0 1.0 0.1 1.0 (5') Carboxyvinyl polymer - - - - - - - (6) Self-emulsitying glyceryl monostearate 3.0 3.0 3.0 3.0 3.0 3.0 3.0 (7) PEG-100 stearate 2.0 2.0 2.0 2.0 2.0 2.0 2.0 (8) Stearic acid 0.1 0.1 0.1 0.1 0.1 0.1 0.1 (9) Palmitic acid 0.3 0.3 0.3 0.3 0.3 0.3 0.3 (10) Sodium hydroxide Proper amount Proper amount Proper amount Proper amount Proper amount Proper amount Proper amount (11) Myristyl myristate 2.0 2.0 2.0 2.0 2.0 2.0 2.0 (12) Isodecyl neopentanoate [ingredient (C)] 1.0 8.0 15.0 8.0 10.0 1.0 1.0 (13) Squalane - - - - - - - (14) Dimethylsilicone (5 mPa·s) 5.0 5.0 5.0 5.0 5.0 5.0 5.0 (15) Hydrogenated polyisobutene 5.0 5.0 5.0 5.0 5.0 5.0 5.0 (16) 2-ethylhexyl-2-cyano-3,3-diphenylacrylate 1.0 1.0 1.0 1.0 1.0 1.0 1.0 (17) Edetate 0.1 0.1 0.1 0.1 0.1 0.1 0.1 (18) Phenoxyethanol 0.5 0.5 0.5 0.5 0.5 0.5 0.5 (19) Perfume 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Stability ⊙ ⊙ ⊙ ⊙ ⊙ ⊙ ⊙ Texture (Spreadability on skin) ⊙ ⊙ ⊙ ⊙ ⊙ ⊙ ⊙ (stickiness) ⊙ ⊙ ⊙ ⊙ ⊙ ⊙ ⊙ (lightness) ⊙ ⊙ ⊙ ⊙ ⊙ ⊙ ⊙ Skin improving effect (skin resilience) ⊙ ⊙ ⊙ ⊙ ⊙ ⊙ ⊙ (skin moisturizing) ⊙ ⊙ ⊙ ⊙ ⊙ ⊙ ⊙ -
[Table 2] Ingredients Example 1 2 3 4 5 6 (1) Ion-exchanged water Balance Balance Balance Balance Balance Balance (2) D-alanine [ingredient (A)] - 3.0 3.0 1.0 3.0 3.0 (3) Glycerin [ingredient (D)] 5.0 5.0 5.0 5.0 5.0 - (4) 1,3-butylene glycol 3.0 3.0 3.0 3.0 3.0 3.0 (5) Vinylpyrrolidone/sodium 2-acrylamido-methylpropanesulfonate copolymer [ingredient (B)] 1.0 - 1.0 - 1.0 1.0 (5') Carboxyvinyl polymer - - - 0.2 - - (6) Self-emulsifying glyceryl monostearate 3.0 3.0 3.0 3.0 3.0 3.0 (7) PEG-100 stearate 2.0 2.0 2.0 2.0 2.0 2.0 (8) Stearic acid 0.1 0.1 0.1 0.1 0.1 0.1 (9) Palmitic acid 0.3 0.3 0.3 0.3 0.3 0.3 (10) Sodium hydroxide Proper amount Proper amount Proper amount Proper amount Proper amount Proper amount (11) Myristyl myristate 2.0 2.0 2.0 2.0 2.0 2.0 (12) Isodecyl neopentanoate [ingredient (C)] 8.0 8.0 - 8.0 - 8.0 (13) Squalane - - - - 8.0 - (14) Dimethylsilicone (5 mPa·s) 5.0 5.0 5.0 5.0 5.0 5.0 (15) Hydrogenated polyisobutene 5.0 5.0 5.0 5.0 5.0 5.0 (16) 2-ethylhexyl-2-cyano-3,3-diphenylacrylate 1.0 1.0 1.0 1.0 1.0 1.0 (17) Edetate 0.1 0.1 0.1 0.1 0.1 0.1 (18) Phenoxyethanol 0.5 0.5 0.5 0.5 0.5 0.5 (19) Perfume 0.1 0.1 0.1 0.1 0.1 0.1 Stability ⊙ × ⊙ ○ ⊙ ⊙ Texture (Spreadability on skin) ⊙ ⊙ Δ ⊙ × Δ (stickiness) Δ ⊙ × Δ × ⊙ (lightness) ⊙ ⊙ × Δ × ⊙ Skin improving effect (skin resilience) ⊙ × ⊙ Δ ○ × (skin moisturizing) Δ ⊙ ⊙ Δ ⊙ × - Tables 1 and 2 show that Examples 1 to 7 according to the invention are excellent in stability, texture, and skin improving effect. In contrast, not all of stability, texture, and skin improving effect are satisfactory with respect to Comparative Examples 1 to 6, which do not satisfy the requirements of the invention.
Specifically, Comparative Examples 1 to 3 and 6 lack any of the ingredients (A) , (B) , (C) , and (D) . Comparative Example 1 not containing the ingredient (A) is sticky and lacks a skin moisturizing effect. Comparative Example 2 not containing the ingredient (B) particularly has a problem with stability. Comparative Example 3 not containing the ingredient (C) is significantly inferior in texture such as spreadability on skin, stickiness, or lightness. Comparative Example 6 not containing the ingredient (D) does not produce a skin improving effect such as a skin moisturizing effect. - Comparative Example 4 containing another thickener (carboxyvinyl polymer) instead of the ingredient (B) is insufficient in texture with respect to stickiness, lightness, etc. and insufficient in skin improving effect. Comparative Example 5 containing squalane with an IOB of 0 instead of the ingredient (C) is sticky and lacks spreadability on skin and lightness, although it makes the skin resilient and moisturized.
- Hereinafter, other examples of the invention are shown.
-
(Ingredients) % by mass (1) Liquid paraffin 2.0 (2) Decamethylcyclopentanesiloxane 5.0 (3) Isodecyl benzoate (IOB=0.23) [ingredient (C)] 5.0 (4) Polyoxyethylene (21) stearyl ether 2.0 (5) Polyoxyethylene (2) stearyl ether 0.5 (6) Cetyl alcohol 2.5 (7) Batyl alcohol 2.0 (8) Perfume 0.1 (9) Ion-exchanged water q.s. (10) Dipropylene glycol 3.0 (11) Glycerin [ingredient (D)] 11.0 (12) Paraben 0.15 (13) Ethanol 3.0 (14) Potassium hydroxide 0.4 (15) Dimethylacrylamide/sodium 2-acrylamido-2-methylpropanesulfonate crosspolymer [ingredient (B)] 0.8 (Trade name: SU-POLYMER G-1, manufactured by TOHO Chemical Industry Co., Ltd.) (16) Citric acid 0.01 (17) Sodium citrate 0.09 (18) D-hydroxyproline [ingredient (A)] 2.0 - Ingredients (1) to (8) were uniformly mixed and dissolved at 70°C (oil phase) . On the other hand, ingredients (9) to (18) were uniformly mixed and dissolved at 70°C (aqueous phase) . While the oil phase was gradually added to the aqueous phase kept at 70°C, the mixture was emulsified with a homomixer. After the emulsification was completed, the emulsion was rapidly cooled to 40°C or less to give the desired anti-aging cream.
- The resulting cream was evaluated in the same manner as described above for Examples 1 to 7. As a result, the cream had good texture (the evaluation was ⊙ with respect to all of skin spreadability, stickiness, and lightness) , a moisturizing effect, light spreadability, and a moist feeling with lightness when applied to the skin, and also had good stability (the stability was evaluated "O").
-
(Ingredients) % by mass (1) Octyl p-methoxycinnamate 6.0 (2) Glyceryloctyl di-p-methoxycinnamate 2.0 (3) 4-tert-butyl-4'-methoxybenzoylmethane 2.0 (4) Pentaerythritol tetra(octanoate/p-methoxycinnamate) 3.0 (5) Tripropylene glycol dineopentanoate (IOB=0.52) [ingredient (C)] 5.0 (6) Dimethylpolysiloxane (20 mPa·s) 3.0 (7) Petrolatum 0.5 (8) PEG (40) glyceryl isostearate 1.2 (9) Sorbitan tristearate 0.25 (10) Ion-exchanged water balance (11) 1,3-butylene glycol 3.0 (12) Glycerin [ingredient (D)] 5.0 (13) Ethanol 3.0 (14) Acrylamide/sodium 2-acrylamido-2-methylpropanesulfonate (40% in active content) [ingredient (B)] 1.0 (0.4) (Trade name: SEPIGEL 305, manufactured by SEPIC) (15) Perfume 0.1 (16) D-methionine [ingredient (A)] 0.5 - Ingredients (1) to (9) were uniformly mixed and dissolved at 70°C (oil phase). On the other hand, ingredients (10) to (16) were uniformly mixed and dissolved at 70°C (aqueous phase) . While the oil phase was gradually added to the aqueous phase kept at 70°C, the mixture was emulsified with a homomixer. After the emulsification was completed, the emulsion was rapidly cooled to 40°C or less to give the desired O/W emulsion type sunscreen.
- The resulting sunscreen was evaluated in the same manner as Examples 1 to 7. As a result, the sunscreen had good texture (the evaluation was ⊙ with respect to all of skin spreadability, stickiness, and lightness), a moisturizing effect, light spreadability, and a moist feeling with lightness when applied to the skin, and also had good stability (the stability was evaluated "O") .
-
(Ingredients) % by mass (1) Hydrogenated polyisobutene 2.0 (2) Isododecane 6.0 (3) Isodecyl benzoate (IOB=0.23) [ingredient (C)] 3.0 (4) Polyoxyethylene (30) behenyl ether 3.0 (5) Cetyl alcohol 2.5 (6) Batyl alcohol 2.5 (7) Perfume 0.1 (8) Ion-exchanged water balance (9) 1,3-butylene glycol 3.0 (10) Glycerin [ingredient (D)] 6.0 (11) Arbutin 5.0 (12) Magnesium ascorbate phosphate 1.0 (13) Paraben 0.15 (14) Ethanol 3.0 (15) Potassium hydroxide q.s. (16) (Hydroxyethyl acrylate/sodium 2-acrylamido-2-methylpropanesulfonate) copolymer (37.5% in active content) [ingredient (B)] 1.3 (0.49) (trade name: SIMULGEL NS, manufactured by SEPIC) (17) Citric acid 0.01 (18) Sodium citrate 0.09 (19) D-serine [ingredient (A)] 2.5 - Ingredients (1) to (7) were uniformly mixed and dissolved at 70°C (oil phase). On the other hand, ingredients (8) to (19) were uniformly mixed and dissolved at 70°C (aqueous phase). While the oil phase was gradually added to the aqueous phase kept at 70°C, the mixture was emulsified with a homomixer. After the emulsification was completed, the emulsion was rapidly cooled to 40°C or less to give the desired whitening cream.
- The resulting whitening cream was evaluated in the same manner as Examples 1 to 7. As a result, the cream had good texture (the evaluation was ⊙ with respect to all of skin spreadability, stickiness, and lightness), a moisturizing effect, light spreadability, and a moist feeling with lightness when applied to the skin, and also had good stability (the stability was evaluated "O").
-
(Ingredients) % by mass (1) Liquid paraffin 2.0 (2) Dimethysilicone (1.5 mPa·s) 6.0 (3) Isononyl isononanoate (IOB=0.2) [ingredient (C)] 3.0 (4) Polyoxyethylene (20) sorbitan monostearate 3.0 (5) Sorbitan trioleate 0.3 (6) Cetyl alcohol 2.5 (7) Batyl alcohol 1.0 (8) Perfume 0.1 (9) 1,3-butylene glycol 5.0 (10) Glycerin [ingredient (D)] 7.0 (11) Ion-exchanged water balance (12) Trimethylglycine 0.1 (13) Potassium 4-methoxysalicylate 2.0 (14) Phenoxyethanol 0.2 (15) Sodium hydroxide q.s. (16) (Hydroxyethyl acrylate/sodium 2-acrylamido-2-methylpropanesulfonate) copolymer [ingredient (B)] 1.5 (trade name: SEPINOV EMT 10, manufactured by SEPIC) (17) Citric acid 0.02 (18) Sodium citrate 0.08 (19) D-glutamic acid [ingredient (A)] 0.5 (20) D-aspartic acid [ingredient (A)] 1.0 - Ingredients (1) to (8) were uniformly mixed and dissolved at 70°C (oil phase). On the other hand, ingredients (9) to (20) were uniformly mixed and dissolved at 70°C (aqueous phase). While the oil phase was gradually added to the aqueous phase kept at 70°C, the mixture was emulsified with a homomixer. After the emulsification was completed, the emulsion was rapidly cooled to 40°C or less to give the desired whitening cream.
- The resulting whitening cream was evaluated in the same manner as Examples 1 to 7. As a result, the cream had good texture (the evaluation was ⊙ with respect to all of skin spreadability, stickiness, and lightness), a moisturizing effect, light spreadability, and a moist feeling with lightness when applied to the skin, and also had good stability (the stability was evaluated "O").
Claims (5)
- An oil-in-water type emulsion skin cosmetic composition, comprising:(A) a D-amino acid or a derivative or salt thereof;(B) a homopolymer, a copolymer, or a crosspolymer comprising, as a constituent unit, one or more selected from 2-acrylamido-2-methylpropanesulfonic acid, acrylic acid, and derivatives thereof;(C) an ester oil with an IOB value of 0.2 to 0.6; and(D) glycerin.
- The oil-in-water emulsion skin cosmetic composition according to claim 1,
wherein the D-amino acid is selected from the group consisting of D-glutamic acid, D-alanine, D-methionine, D-hydroxyproline, D-aspartic acid, D-cysteine, D-serine, and D-proline. - The oil-in-water emulsion skin cosmetic composition according to claim 1 or 2, which contains0.1 to 5.0% by mass of the ingredient (A),0.1 to 2.0% by mass of the ingredient (B),1.0 to 15.0% by mass of the ingredient (C), and5.0 to 15.0% by mass of the ingredient (D) based on the total amount of the cosmetic composition.
- The oil-in-water emulsion skin cosmetic composition according to any one of claims 1 to 3,
wherein the ingredient (B) is one or more selected from a vinylpyrrolidone/2-acrylamido-2-methylpropanesulfonic acid (salt) copolymer, a dimethylacrylamide/2-acrylamido-2-methylpropanesulfonic acid (salt) copolymer, an acrylamide/acrylic acid/2-acrylamido-2-methylpropanesulfonic acid (salt) copolymer, a mixture of polyacrylamide and polyacrylic acid (salt), a sodium acrylate/2-acrylamido-2-methylpropanesulfonic acid (salt) copolymer, an acrylamide/acrylic acid (salt) copolymer, a homopolymer of 2-acrylamido-2-methylpropanesulfonic acid (salt), and a vinylformamide/2-acrylamido-2-methylpropanesulfonic acid (salt) copolymer. - The oil-in-water emulsion skin cosmetic composition according to any one of claims 1 to 4,
wherein the ingredient (C) is one or more selected from tripropylene glycol dineopentanoate (IOB=0.52), isodecyl benzoate (IOB=0.23), propylene glycol dicaprylate (IOB=0.32), isononyl isononanoate (IOB=0.2), cetyl 2-ethylhexanoate (IOB=0.52), glyceryl tri-2-ethylhexanoate (IOB=0.36), isodecyl neopentanoate (IOB=0.22), 2-ethylhexyl 2-ethylhexanoate (IOB=0.2), pentaerythritol tetra-2-ethylhexanoate (IOB=0.35), di-2-ethylhexyl succinate (IOB=0.32), and 2-ethylhexyl isononanoate (IOB=0.2).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010138388 | 2010-06-17 | ||
JP2011125099A JP5689026B2 (en) | 2010-06-17 | 2011-06-03 | Oil-in-water emulsified skin cosmetic |
PCT/JP2011/062892 WO2011158678A1 (en) | 2010-06-17 | 2011-06-06 | Oil-in-water type emulsion skin cosmetic |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2583663A1 true EP2583663A1 (en) | 2013-04-24 |
EP2583663A4 EP2583663A4 (en) | 2015-08-19 |
EP2583663B1 EP2583663B1 (en) | 2019-04-03 |
Family
ID=45348084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11795586.4A Active EP2583663B1 (en) | 2010-06-17 | 2011-06-06 | Oil-in-water type emulsion skin cosmetic |
Country Status (8)
Country | Link |
---|---|
US (1) | US8697750B2 (en) |
EP (1) | EP2583663B1 (en) |
JP (1) | JP5689026B2 (en) |
KR (1) | KR101692801B1 (en) |
CN (1) | CN102946849B (en) |
ES (1) | ES2726452T3 (en) |
TW (1) | TWI495483B (en) |
WO (1) | WO2011158678A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2762128A1 (en) * | 2011-09-30 | 2014-08-06 | Shiseido Company, Ltd. | Oil-in-water-type emulsion cosmetic |
WO2015164290A1 (en) * | 2014-04-23 | 2015-10-29 | The Procter & Gamble Company | Cosmetic compositions having reduced irritation |
WO2018096224A1 (en) * | 2016-11-25 | 2018-05-31 | Urgo Recherche Innovation Et Developpement | Film-forming composition |
RU2666253C2 (en) * | 2013-07-12 | 2018-09-06 | Пьер Фабр Дермо-Косметик | Cosmetic composition comprising a ternary lipid association for controlling dryness of the skin |
EP3533440A4 (en) * | 2016-10-31 | 2020-06-17 | Shiseido Co., Ltd. | Oil-in-water type dermatological composition for external use |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012097149A1 (en) | 2011-01-14 | 2012-07-19 | Dow Agrosciences Llc | Agricultural compositions comprising oil-in-water emulsions |
US10281267B2 (en) | 2014-11-10 | 2019-05-07 | Shiseido Company, Ltd. | Method for evaluating flow of skin, method for examining skin glow improvers, and skin glow improver |
WO2018056989A1 (en) | 2016-09-22 | 2018-03-29 | Colgate-Palmolive Company | Personal care gel and method |
JP7172985B2 (en) * | 2017-03-24 | 2022-11-16 | 味の素株式会社 | whitening agent |
CN108670890B (en) * | 2018-07-17 | 2020-06-26 | 广州澳希亚实业有限公司 | Organic sunscreen composition and application thereof |
EP3903762A4 (en) * | 2018-12-28 | 2022-10-26 | Shiseido Company, Ltd. | Retinol-containing oil-in-water type emulsified cosmetic material |
FR3142086A1 (en) * | 2022-11-17 | 2024-05-24 | L'oreal | COMPOSITION COMPRISING A LARGE QUANTITY OF POLYOL |
WO2024075555A1 (en) * | 2022-10-04 | 2024-04-11 | L'oreal | Composition comprising large amount of polyol |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4482537A (en) * | 1983-09-19 | 1984-11-13 | Charles Of The Ritz Group Ltd. | Skin conditioning composition |
JPS6467685A (en) | 1987-09-09 | 1989-03-14 | Hitachi Ltd | Wiring method for wiring length designation |
US5061721A (en) * | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
FR2750327B1 (en) | 1996-06-28 | 1998-08-14 | Oreal | COMPOSITION FOR TOPICAL USE IN THE FORM OF OIL-IN-WATER EMULSION WITHOUT SURFACTANT CONTAINING A POLY (2-ACRYLAMIDO 2-METHYLPROPANE SULFONIC) CROSSLINKED AND NEUTRALIZED |
JPH1160436A (en) * | 1997-08-20 | 1999-03-02 | Shiseido Co Ltd | Cosmetic for improving chapped skin |
JP3834960B2 (en) | 1997-10-14 | 2006-10-18 | 味の素株式会社 | Method for producing D-amino acid |
JPH11246329A (en) | 1998-02-27 | 1999-09-14 | Shiseido Co Ltd | Skin preparation for external use |
JP3589283B2 (en) | 1998-12-25 | 2004-11-17 | ライオン株式会社 | Hair cosmetics |
JP3681154B2 (en) | 1999-10-14 | 2005-08-10 | 株式会社資生堂 | Water-soluble thickener and cosmetics containing the same |
JP2002356416A (en) | 2001-05-30 | 2002-12-13 | Shiseido Co Ltd | Water-in-oil type emulsified cosmetic for preventing rough skin |
JP3682419B2 (en) * | 2001-06-19 | 2005-08-10 | 株式会社ノエビア | Topical skin preparation |
JP4838537B2 (en) * | 2005-05-25 | 2011-12-14 | 株式会社 資生堂 | Inadequate keratinization inhibitor, pore-reducing agent, skin roughening preventive / improving agent, and composition for external use on skin |
JP2008001654A (en) * | 2006-06-23 | 2008-01-10 | Ajinomoto Co Inc | External preparation for skin |
JP4968722B2 (en) * | 2006-09-22 | 2012-07-04 | 株式会社 資生堂 | Oil-in-water emulsified skin cosmetic |
KR101392380B1 (en) * | 2007-02-21 | 2014-05-07 | 주식회사 엘지생활건강 | Powder detergent granule containing acidic water-soluble polymer and manufacturing method thereof |
FR2916351B1 (en) * | 2007-05-22 | 2012-12-07 | Galderma Res & Dev | PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST TWO COMPOUNDS SELECTED BY PYRROLIDONE-5-CARBOXYLIC ACID, CITRULLINE, ARGININE AND ASPARAGINE AND THEIR USE IN THE TREATMENT OF ATOPIC DERMATITIS |
CN101925353A (en) * | 2008-01-21 | 2010-12-22 | 株式会社资生堂 | VEGFC production promoter |
JP5277011B2 (en) * | 2008-02-13 | 2013-08-28 | 株式会社 資生堂 | Oil-in-water emulsified cloudy skin cosmetic |
JP5180633B2 (en) * | 2008-03-14 | 2013-04-10 | 花王株式会社 | Skin cleanser |
JP2009298752A (en) * | 2008-06-17 | 2009-12-24 | Shiseido Co Ltd | Skin care preparation composition for external use |
DE102008047944A1 (en) * | 2008-09-18 | 2009-06-25 | Henkel Ag & Co. Kgaa | Cosmetic or dermatological composition, useful e.g. for cosmetic tanning of human hair and for coloring of the hair, comprises an alpha-melanocyte-stimulating hormone analogue and acetyl-methionyl-arginine-ethyl ester |
US8926996B2 (en) * | 2008-12-03 | 2015-01-06 | Shiseido Company, Ltd. | Oil-in-water cosmetics |
-
2011
- 2011-06-03 JP JP2011125099A patent/JP5689026B2/en active Active
- 2011-06-06 ES ES11795586T patent/ES2726452T3/en active Active
- 2011-06-06 US US13/701,942 patent/US8697750B2/en active Active
- 2011-06-06 CN CN201180029884.8A patent/CN102946849B/en active Active
- 2011-06-06 KR KR1020127031708A patent/KR101692801B1/en active IP Right Grant
- 2011-06-06 EP EP11795586.4A patent/EP2583663B1/en active Active
- 2011-06-06 WO PCT/JP2011/062892 patent/WO2011158678A1/en active Application Filing
- 2011-06-16 TW TW100121084A patent/TWI495483B/en not_active IP Right Cessation
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2762128A1 (en) * | 2011-09-30 | 2014-08-06 | Shiseido Company, Ltd. | Oil-in-water-type emulsion cosmetic |
EP2762128A4 (en) * | 2011-09-30 | 2015-04-29 | Shiseido Co Ltd | Oil-in-water-type emulsion cosmetic |
US9956148B2 (en) | 2011-09-30 | 2018-05-01 | Shiseido Company, Ltd. | Oil-in-water-type emulsion cosmetic |
RU2666253C2 (en) * | 2013-07-12 | 2018-09-06 | Пьер Фабр Дермо-Косметик | Cosmetic composition comprising a ternary lipid association for controlling dryness of the skin |
WO2015164290A1 (en) * | 2014-04-23 | 2015-10-29 | The Procter & Gamble Company | Cosmetic compositions having reduced irritation |
US9480634B2 (en) | 2014-04-23 | 2016-11-01 | The Procter & Gamble Company | Cosmetic compositions |
EP3533440A4 (en) * | 2016-10-31 | 2020-06-17 | Shiseido Co., Ltd. | Oil-in-water type dermatological composition for external use |
US12059489B2 (en) | 2016-10-31 | 2024-08-13 | Shiseido Company, Ltd. | Oil-in-water type dermatological composition for external use |
WO2018096224A1 (en) * | 2016-11-25 | 2018-05-31 | Urgo Recherche Innovation Et Developpement | Film-forming composition |
Also Published As
Publication number | Publication date |
---|---|
KR20130109949A (en) | 2013-10-08 |
US20130079410A1 (en) | 2013-03-28 |
WO2011158678A1 (en) | 2011-12-22 |
EP2583663A4 (en) | 2015-08-19 |
US8697750B2 (en) | 2014-04-15 |
CN102946849A (en) | 2013-02-27 |
EP2583663B1 (en) | 2019-04-03 |
TWI495483B (en) | 2015-08-11 |
TW201208710A (en) | 2012-03-01 |
JP5689026B2 (en) | 2015-03-25 |
JP2012020988A (en) | 2012-02-02 |
KR101692801B1 (en) | 2017-01-05 |
ES2726452T3 (en) | 2019-10-04 |
CN102946849B (en) | 2015-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8697750B2 (en) | Oil-in-water type emulsion skin cosmetic | |
JP4679350B2 (en) | Oil-in-water emulsified skin cosmetic | |
EP2786745B1 (en) | Aqueous cosmetic preparation for skin | |
EP2740462B1 (en) | Oil-in-water-type emulsion cosmetic | |
JP4968722B2 (en) | Oil-in-water emulsified skin cosmetic | |
EP2301522B1 (en) | Water-in-oil emulsion-type cosmetic preparation | |
US8980234B2 (en) | Cosmetic composition comprising an ascorbic acid or salicylic acid compound | |
KR20060130215A (en) | Oil-in-water emulsified composition, and external preparation for skin and cosmetics using the composition | |
US20200345596A1 (en) | Skin-tightening composition | |
JP4827433B2 (en) | Oil-in-water emulsified skin cosmetic | |
WO2012017733A1 (en) | Skin cosmetic | |
ES2351381T3 (en) | COSMETIC COMPOSITION THAT INCLUDES AN ASCORBIC ACID COMPOUND OR A SALICYLIC ACID COMPOUND. | |
JP5506106B2 (en) | Oil-in-water emulsified skin cosmetic | |
JP2013063935A (en) | Oil-in-water emulsion skin cosmetic | |
JP5398813B2 (en) | Aqueous skin cosmetics | |
JP5088979B1 (en) | Oil-in-water emulsified skin cosmetic | |
JP2007145719A (en) | Emulsified type external preparation for skin | |
JP2016084323A (en) | Cosmetics and skin condition improving method | |
JP2021161112A (en) | Composition | |
JP2016204317A (en) | Skin external preparation | |
JP2006143686A (en) | Emulsion composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130108 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20150717 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 8/81 20060101ALI20150713BHEP Ipc: A61K 8/37 20060101ALI20150713BHEP Ipc: A61Q 19/00 20060101ALI20150713BHEP Ipc: A61K 8/06 20060101ALI20150713BHEP Ipc: A61K 8/44 20060101AFI20150713BHEP Ipc: A61K 8/34 20060101ALI20150713BHEP Ipc: A61Q 19/02 20060101ALI20150713BHEP Ipc: A61Q 17/04 20060101ALI20150713BHEP |
|
17Q | First examination report despatched |
Effective date: 20160926 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20181008 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1114855 Country of ref document: AT Kind code of ref document: T Effective date: 20190415 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602011057796 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20190403 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1114855 Country of ref document: AT Kind code of ref document: T Effective date: 20190403 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2726452 Country of ref document: ES Kind code of ref document: T3 Effective date: 20191004 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190803 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20190624 Year of fee payment: 9 Ref country code: IT Payment date: 20190726 Year of fee payment: 9 Ref country code: ES Payment date: 20190723 Year of fee payment: 9 Ref country code: DE Payment date: 20190628 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190703 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190704 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190803 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602011057796 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 |
|
26N | No opposition filed |
Effective date: 20200106 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20190630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190606 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190630 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190630 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190606 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190630 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602011057796 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20200606 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200606 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20110606 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20211026 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200606 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200607 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190403 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230613 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240521 Year of fee payment: 14 |